---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000128"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T03:06:42.775073+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Senti Bio doses first patient in SN301A CAR-NK trial for liver cancer in China

## Summary
- First patient dosed in SN301A pilot trial for advanced GPC3-expressing HCC in mainland China.
- SN301A is SENTI-301A CAR-NK product candidate manufactured and developed by Celest Therapeutics.
- Open-label, single-center study (NCT06652243) evaluating safety, pharmacokinetics, and anti-tumor activity.
- Three dose levels administered in 28-day cycles with lymphodepletion conditioning.
- Over 40% of global HCC cases occur in China; Senti retains rights outside Greater China.

## SEC filing metadata
- accession: 0001854270-24-000128
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/0001854270-24-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/snti-20241216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000128
- JSON: https://secwatch.observer/filing/0001854270-24-000128.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.